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Histological Subtypes of Lung Adenocarcinoma Have
Differential 18F-Fluorodeoxyglucose Uptakes on the
Positron Emission Tomography/Computed
Tomography Scan
Chao-Hua Chiu, MD,*†‡ Yi-Chen Yeh, MD,*§ Ko-Han Lin, MD, Yu-Chun Wu, MD,¶
Yu-Chin Lee, MD,†‡ Teh-Ying Chou, MD, PhD,*§ and Chun-Ming Tsai, MD†‡
Introduction: Previous studies have shown that lung squamous cell
carcinoma has higher 18F-fluorodeoxyglucose (FDG) uptake on
positron emission tomography (PET) than adenocarcinoma. We
hypothesized that histological subtypes of lung adenocarcinoma
were also different in 18F-FDG uptake.
Methods: Patients who had preoperative PET/computed tomogra-
phy (CT) scan and had undergone complete resection for lung
adenocarcinoma between April 2007 and December 2009 were
enrolled in this study. Because of the limitation of spatial resolution
on PET/CT, tumors less than 1 cm were excluded for analysis. Two
independent classification systems were used to categorize histolog-
ical subtypes of adenocarcinoma; one was modified from the current
World Health Organization classification and the other used the
morphological features of the terminal respiratory unit (TRU).
The maximal standardized uptake value (SUVmax) on PET/CT
and the glucose transporter type 1 (GLUT-1) expression of the
tumors were measured and correlated to the histology of lung
adenocarcinoma.
Results: One hundred fifty-two patients with 153 primary lung
adenocarcinomas were included. There was a significant difference
in SUVmax among different histological subtypes. Namely, solid
predominant adenocarcinomas had significantly higher SUVmax
than those with other predominant histology (p  0.001), and
TRU-type adenocarcinomas had significantly lower SUVmax than
non-TRU-type adenocarcinomas (p  0.001). Consistently,
GLUT-1 expression was higher in tumors with a solid growth
pattern than those without (p  0.001) and in tumors with non-TRU
type than TRU type (p  0.001).
Conclusions: The histological subtypes of lung adenocarcinomas
differ in GLUT-1 expression and 18F-FDG uptake on the PET/CT
scan, suggesting that histological subtyping not only has morpho-
logical but also biological implications.
Key Words: Lung adenocarcinoma, Histological subtyping, 18F-
fluorodeoxyglucose, Positron emission tomography, Glucose trans-
porter type 1.
(J Thorac Oncol. 2011;6: 1697–1703)
Altered metabolism is one of the hallmarks of cancer,1,2and increased utilization of glucose is the first to be
discovered.3 It is the basic principle for the development of
18F-fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) in oncology.4 18F-FDG-PET is now widely used in
the clinical diagnosis and staging of variable types of cancers,
including non-small cell lung cancer.
Previous studies have consistently shown that pulmo-
nary squamous cell carcinoma displays higher glucose trans-
porter type 1 (GLUT-1) expression and 18F-FDG uptake than
adenocarcinoma.5–7 However, whether histological subtypes
of adenocarcinoma also differ in 18F-FDG uptake is still not
clear. In the current World Health Organization (WHO)
classification of lung cancer, adenocarcinomas are mainly
categorized as acinar, papillary, bronchioloalveolar, solid
with mucin production, and mixed type.8 This classification is
not clinically useful because pure subtype adenocarcinoma is
rare. In the new International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Soci-
ety (IASLC/ATS/ERS) international multidisciplinary classifi-
cation, the category of mixed type is no longer used, and
adenocarcinoma is classified according to its predominant his-
tology.9 Previous studies have already used this approach and
found significant prognostic implication of this classification.10–12
In addition to the WHO classification, there are other
classification systems. For example, Japanese researchers
used the morphological features of the terminal respiratory
unit (TRU) to classify lung adenocarcinomas as TRU type or
non-TRU type.13 Besides morphological differences, TRU-
type adenocarcinoma is more likely to contain thyroid tran-
scription factor-1 (TTF-1) expression and epidermal growth
factor receptor (EGFR) mutations,13,14 implying that the mo-
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lecular mechanism of carcinogenesis varies between TRU-
type and non-TRU-type adenocarcinomas.14,15 A possible
difference in 18F-FDG uptake between these two types of
adenocarcinoma has not been elucidated.
In this study, we hypothesized that histological subtypes
of lung adenocarcinoma were different in 18F-FDG uptake.
Using two independent classification systems, we evaluated the
18F-FDG uptake on PET/computed tomography (CT) in various
histological subtypes of lung adenocarcinoma. We showed a
significant difference in standardized uptake value (SUV), a
semiquantitative parameter to evaluate 18F-FDG uptake, among
various histological subtypes of lung adenocarcinoma and a
correlation with GLUT-1 expression. Our study results support
that lung adenocarcinoma comprises a heterogeneous group of
diseases, and histological subtyping possesses both morpholog-
ical and biological implications.
PATIENTS AND METHODS
Patients
We identified a cohort of patients who underwent
complete surgical resection for lung adenocarcinoma at a
tertiary medical center during the period of April 2007
through December 2009. Patients were included if they had
undergone a preoperative PET/CT scan. Tumors less than 1
cm in diameter were excluded because of the consideration
that the limited spatial resolution of PET/CT might interfere
with the interpretation. The pathological staging was based
on the 7th edition of the tumor, node, metastasis classification
for lung cancer.16 This study was first approved by the
Committee of Pathology Specimen and then was approved by
the Institution Review Board of Taipei Veterans General
Hospital. All patients had provided written informed consent
to the Residual Sample Bank before operation.
Histological Classification
Two classifications of lung adenocarcinoma were used.
The first was modified from the current WHO classification8
with the approach proposed by the new IASLC/ATS/ERS
international multidisciplinary classification.9 Tumors were
recorded for the percentage of each morphological growth
pattern, namely, solid, papillary, acinar, and lepidic growth,
in a 5% increment and classified according to the most
predominant growth pattern. The second classification system
was modified from the studies of Dr. Yatabe.13,14 Tumors
were classified as TRU type if the cancer cells were charac-
terized morphologically by a cuboidal or dome-shaped free
cell contour. Non-TRU-type cancer cells were characterized
by their smoothly contoured luminal border. In both classi-
fication systems, a population of less than 10% was consid-
ered insignificant.
18F-FDG PET/CT
All patients fasted for at least 6 hours, and their blood
glucose levels were required to be less than 180 mg/dl before
examination. Fifty minutes after intravenous injection of 370
MBq of 18F-FDG, the PET/CT imaging was obtained from
the head to the upper portion of the thigh on an integrated
PET/CT scanner (Discovery VCT, GE Healthcare, Wauke-
sha, WI). A low-dose CT scan for attenuation correction and
localization was performed with a 64-slice multidetector CT
of the hybrid scanner, followed by an emission scan with
3D-mode acquisition. The raw data of PET imaging were
reconstructed into a 128  128 matrix using an iterative
reconstruction algorithm (iteration 2 and subset 28). For
semiquantitative analysis of 18F-FDG uptake, SUV was as-
sessed on the Xeleris Workstation (GE Healthcare). The
maximal SUV (SUVmax) of the lung tumor was measured by
drawing a 1.0-cm diameter region of interest within the lesion
on the slice with the highest uptake.
Immunohistochemical Staining of GLUT-1
Tumor specimens from patients who underwent surgery
between March 2008 and December 2009 were available and
approved for further testing. Immunohistochemical staining
was performed as described previously.17 Briefly, representative
sections (3 m in thickness) were cut from the formalin-fixed
paraffin-embedded block. Tissue slides were heated at 56°C
overnight, deparaffinized with xylene, and rehydrated with eth-
anol. Slides were then placed evenly in a prewarmed 0.1 M
citrate buffer (pH 6.4) and heated in a microwave for antigen
retrieval. Hydrogen peroxide (3%) was used to block endog-
enous peroxidase. A rabbit antihuman GLUT-1 polyclonal
antibody (1:800 dilution; Millipore, Billerica, MA) was then
used to incubate the tissue slides at room temperature for 1
hour. Antigen-antibody reactions were visualized after slides
were reacted with a secondary antibody (Dako REAL EnVision
Detection System, Dako Denmark A/S, Denmark) at room
temperature for 1 hour. All slides were counterstained with
hematoxylin. The intensity of GLUT-1 staining was catego-
rized using a 4-point scale: 0, same as negative control; 1,
weak staining; 2, moderate staining; and 3, strong stain-
ing. Each slide was read independently by two authors
(C.-H.C. and Y.-C.Y.).
Statistical Analysis
Because the measurement of SUVmax is semiquantita-
tive and the distribution was not normal, nonparametric tests
were used to analyze the significance of difference between
groups. Spearman rank correlation was performed to analyze
the correlation between the percentage of specific growth
pattern and SUVmax and between GLUT-1 expression and
SUVmax. A p value less than 0.05 was considered statisti-
cally significant. When multiple comparisons were per-
formed, the cutoff level of  error was reduced to 0.05/
(number of tests) (Bonferroni correction). SPSS Statistics
17.0 (SPSS Inc., Chicago, IL) was used to carry out the
analysis and construct the figures.
RESULTS
Patient and Tumor Characteristics
This study included 152 patients with 153 primary lung
adenocarcinomas. Table 1 summarizes the demographic data
and tumor characteristics of patients. Most tumors (79%)
were stage I or II, and the median size was 2.5 cm (range 
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1.0–7.5 cm). 18F-FDG PET/CT was performed before the
operation by a median of 6 days (range  0–83 days), and
the median SUVmax was 4.5 (range  0.6–19.6).
According to the current WHO classification, only 12
tumors can be categorized into one of the four major subtypes
of adenocarcinoma (7 solid, 3 papillary, 1 acinar, and 1
bronchioloalveolar carcinoma), and the others (92%) were all
mixed-type adenocarcinoma. Using the modified WHO clas-
sification described above, the most common subtype was
papillary predominant adenocarcinoma, followed by acinar,
solid, and lepidic predominant adenocarcinoma. Tumors were
also classified as TRU-type or non-TRU-type adenocarci-
noma as described previously. However, we encountered a
practical problem: we found 18 tumors (11.8%) having both
TRU- and non-TRU-type morphology. We then created a
mixed-type category in this study. TRU-type morphology
was the predominant histology in 13 of the 18 cases.
Association Between Modified WHO
Histological Classification and SUVmax
Using modified WHO histological classification, a sig-
nificant difference in SUVmax was found among the four
major subtypes (p  0.001), and solid predominant adeno-
carcinoma had significantly higher SUVmax than the other
subtypes (all p values0.001; Figure 1A). We also found that
tumors with a solid growth pattern had higher SUVmax than
those without (p  0.001). A positive correlation exhibited
between the percentage of solid growth pattern in a tumor and
its SUVmax (Spearman   0.545, p  0.001; Figure 1B).
Because tumor size has major influence on SUVmax, we
conducted further analysis to determine a possible association
between tumor size and histological subtypes. We found that
tumor size did not differ significantly among the four histo-
logical subtypes (p  0.323).
TABLE 1. Patient Demographics and Tumor Characteristics
n (%)
Gender
Male 69 (45.4)
Female 83 (54.6)
Age (yr)
Median (range) 64 (35–87)
Tumor size (cm)
Median (range) 2.5 (1.0–7.5)
Predominant subtypes
Solid 26 (17.0)
Papillary 74 (48.4)
Acinar 44 (28.8)
Lepidic 8 (5.2)
Others 1 (0.7)
TRU/non-TRU
TRU 52 (34.0)
Non-TRU 83 (54.2)
Mixed 18 (11.8)
Type of operation
Pneumonectomy 1 (0.7)
Lobectomy 138 (90.2)
Segmentectomy 2 (1.3)
Wedge resection 12 (7.8)
Staging
IA 34 (22.2)
IB 69 (45.1)
IIA 16 (10.5)
IIB 7 (4.6)
IIIA 20 (13.1)
IIIB 1 (0.7)
IV 6 (3.9)
SUVmax
Median (range) 4.5 (0.6–19.6)
TRU, terminal respiratory unit; SUVmax, maximal standardized uptake value.
FIGURE 1. SUVmax in different subtypes of lung adenocarcinomas categorized according to the predominant histological growth
pattern. Solid predominant adenocarcinoma has higher SUVmax than other subtypes (A), and there is a correlation between the
percentage of solid growth pattern and SUVmax (B). *p less than 0.001. SUVmax, maximal standardized uptake value.
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Association Between TRU Histological
Classification and SUVmax
To confirm the importance of histology on 18F-FDG-
PET, we next evaluated whether 18F-FDG uptake differed
between TRU-type and non-TRU-type adenocarcinomas. In-
deed, TRU-type adenocarcinoma demonstrated significantly
lower SUVmax than the non-TRU type (p  0.001; Figure
2A). Because we had shown that solid growth pattern had
significant influence on SUVmax and had evaluated tumors
with a solid growth pattern as the non-TRU type, we per-
formed a subgroup analysis (n  108) excluding tumors with
a solid growth pattern. Again, TRU-type adenocarcinomas
exhibited lower SUVmax than nonsolid non-TRU-type ade-
nocarcinomas (p  0.001; Figure 2B).
GLUT-1 Expression in Different Subtypes of
Adenocarcinomas
To explore the mechanism for differential 18F-FDG up-
take in tumors, we evaluated the GLUT-1 expression in 64
patients whose tumor specimens were available. No significant
difference was evidenced in both patient demographics and
tumor characteristics between those who had and had not been
examined for GLUT-1 expression (Supplementary Table 1, Sup-
plemental Digital Content 1, http://links.lww.com/JTO/A100).
In this cohort, 40 tumors (62.5%) had positive staining for
GLUT-1 (weak in 19, moderate in 14, and strong in 7), and
a close correlation between SUVmax and GLUT-1 expres-
sion was found (Spearman   0.536, p  0.001; Figure 3).
Consistent with the observation above, we noted higher
GLUT-1 expression in tumors with a solid growth pattern
than those without (p  0.002) and also in tumors with
non-TRU type than TRU type (p  0.001) (Table 2). In
addition, tumors with an acinar growth pattern had lower
GLUT-1 expression than those without (p  0.008). Inter-
estingly, for those with mixed TRU and non-TRU-type ade-
nocarcinoma, GLUT-1 expression was typically higher in
non-TRU than TRU histology in the same tumor (Figure 4).
Together, these data suggested that subtypes of lung adeno-
carcinomas differed in 18F-FDG uptake, which may exert
through the differential expression of GLUT-1 protein.
DISCUSSION
Adenocarcinoma and squamous cell carcinoma are the
two major types of non-small cell lung cancer, and further
subclassification is not commonly used clinically. However,
increasing evidence indicates that lung adenocarcinoma com-
prises a heterogeneous group of diseases with various prog-
nosis.10–12 Our data supported this hypothesis. We showed
that in two independent classification systems, histological
subtypes of lung adenocarcinoma differed in 18F-FDG up-
take. These results suggest that the dysregulated glucose
metabolism one of the hallmarks of cancer, is dissimilar in
these tumors. Therefore, histological subtyping of lung ade-
nocarcinoma is relevant not only for its morphological sig-
nificance but also for its biological and clinical implications.
In the current WHO classification, lung adenocarci-
noma can be further categorized according to its histology;
however, it is not widely used. The clinical application is
limited because less than 20% of lung adenocarcinomas
FIGURE 2. SUVmax in TRU-type and non-
TRU-type lung adenocarcinomas. TRU-type
adenocarcinoma has significantly lower
SUVmax than the non-TRU type in all patients
(A) and also in the subgroup, excluding
those with a solid growth pattern (B).
SUVmax, maximal standardized uptake
value; TRU, terminal respiratory unit.
FIGURE 3. SUVmax in lung adenocarcinomas categorized
according to the GLUT-1 immunohistochemical staining in-
tensity (p  0.001). SUVmax, maximal standardized uptake
value; GLUT, glucose transporter type 1.
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contain pure histology and most tumors are in the same
category, mixed-type adenocarcinoma.18 Our study concurred
with this finding and showed that 92% of the tumors were
mixed type. However, the histological growth patterns,
namely, acinar, papillary, lepidic, and solid, do have prog-
nostic implications. For example, a solid growth pattern is
associated with poor prognosis19 and bronchioloalveolar car-
cinoma, which is defined by pure lepidic growth pattern
without invasion, demonstrates an excellent outcome.20 Sev-
eral studies have therefore modified the WHO classification
by classifying lung adenocarcinoma according to its predom-
inant histology and have shown the usefulness of this strat-
egy.10–12 In fact, it has been adapted for the new IASLC/
ATS/ERS classification. In this study, we used the same
approach and showed that solid predominant adenocarcino-
mas exhibited higher 18F-FDG uptake than the others and
there was a correlation between the percentage of solid
growth pattern and SUVmax. Because tumors with high SUV
demonstrate aggressive behavior,21,22 our finding provides
further evidence to support that a solid growth pattern in lung
adenocarcinoma associates with poor prognosis.
With regard to the association between lepidic growth
pattern and 18F-FDG uptake, we found a lower SUV in
lepidic predominant adenocarcinoma; however, the differ-
ence did not reach statistical significance (versus papillary
predominant, p  0.049; versus acinar predominant, p 
0.335; Figure 1A). Previous investigators noted a lower SUV
in bronchioloalveolar carcinoma5,23–25; however, contradic-
tory results were also reported.7 Of all patients in this study,
there was only one bronchioloalveolar carcinoma, and less
than 6% (n  8) of tumors were classified as lepidic predom-
inant adenocarcinoma. The SUVmax of these tumors ranged
from 0.8 to 5.0 and half of them were above 2.5 (a common
cutoff value used to differentiate malignant from benign
disease). Because of the limited case number, this study
cannot conclude the role of lepidic growth pattern in 18F-
FDG uptake. A larger cohort of patients is needed to address
this issue.
Recently, Japanese researchers have proposed another
histological classification of lung adenocarcinoma. TRU-type
adenocarcinoma is characterized by a cuboidal or dome-
shaped free cell contour, which is morphologically similar to
type II pneumocytes, Clara cells, or nonciliated bronchiolar
epithelium. Non-TRU-type adenocarcinoma is characterized
by cancer cells with a smoothly contoured luminal border and
basally oriented nuclei. Genetically, TRU-type and non-
TABLE 2. Correlations Between GLUT-1 Expression and
Clinicopathological Variables
GLUT-1 Staining Intensity
p0 1 2 3
Gender (%) 0.136a
Male 25.9 25.9 29.6 18.5
Female 45.9 32.4 16.2 5.4
Age (%) 0.199a
70 yr 31.0 38.1 21.4 9.5
70 yr 50.0 13.6 22.7 13.6
WHO histological pattern
Solid (%)
Absent 50.0 28.3 15.2 6.5 0.002a
Present 5.6 33.3 38.9 22.2
Papillary (%)
Absent 35.7 28.6 7.1 28.6 0.094a
Present 38.0 30.0 26.0 6.0
Acinar (%)
Absent 0 0 50.0 50.0 0.008a
Present 40.0 31.7 20.0 8.3
Lepidic (%)
Absent 30.4 34.8 23.9 10.9 0.294a
Present 55.6 16.7 16.7 11.1
TRU/non-TRU type (%) 0.001a
TRU 69.6 17.4 13.0 0
Non-TRU 21.2 36.4 21.2 21.2
Tumor size (cm) (median) 2.9 2.0 2.5 4.0 0.196b
SUVmax (median) 2.8 4.3 6.7 11.0 0.001b
a Fisher’s exact test.
b Spearman rank correlation test.
WHO, World Health Organization; TRU, terminal respiratory unit; SUVmax,
maximal standardized uptake value.
FIGURE 4. A representative case of
lung adenocarcinoma with mixed TRU
(T) and non-TRU (NT) morphology (A;
HE stain, 20), which is apparently
highlighted by the immunohistochem-
ical staining of GLUT-1 (B). The magni-
fied view of the right field in panel A
shows cancer cells with characteristic
TRU morphology (C; HE stain, 200)
and the GLUT-1 staining is negative
(D). The magnified view of the left
field in panel A shows cancer cells with
characteristic non-TRU morphology (E;
HE stain, 200), and the GLUT-1
staining is strongly positive (F). TRU,
terminal respiratory unit; HE, hematox-
ylin and eosin; GLUT, glucose trans-
porter type 1.
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TRU-type adenocarcinomas are distinct, at least, in the fre-
quencies of TTF-1 expression and EGFR mutations. In this
study, we showed that these two subtypes of lung adenocar-
cinoma also differed in glucose metabolism. TRU-type ade-
nocarcinomas had lower GLUT-1 expression and lower 18F-
FDG uptake than non-TRU-type tumors. Interestingly, in this
series, we identified cases with mixed TRU and non-TRU
histology, and GLUT-1 seemed to be preferentially overex-
pressed in the non-TRU component in the same tumor. This
observation further supports that cancer cells with TRU and
non-TRU morphology are biologically different.
In this study, applying the strategy proposed by previ-
ous researchers,10–12 we modified the current WHO patho-
logical classification by using the predominant histology in a
tumor. This strategy is also used in the new IASLC/ATS/ERS
classification. However, this new system has other modifica-
tions. For example, formerly bronchioloalveolar carcinomas
without invasion are now considered adenocarcinoma in situ
and those with minimal invasion (5 mm) are called mini-
mally invasive adenocarcinomas. In our series, only one case
fulfills the criteria of adenocarcinoma in situ and, therefore, it
will hardly have influence on our study results. The new
classification system separates micropapillary from papillary
growth pattern. In our study, we did not find any association
between papillary growth pattern and SUVmax or GLUT-1
expression. However, because tumors with micropapillary
pattern are considered to have more aggressive biological
behavior, it is possible that micropapillary pattern may asso-
ciate with high 18F-FDG uptake. Further studies are needed to
address this issue.
EGFR mutations at the tyrosine kinase domain are
frequently found in lung adenocarcinomas.9 Several research-
ers have attempted to find the association between EGFR
mutation status and 18F-FDG uptake; however, the results are
inconsistent. Some suggested that tumors with EGFR muta-
tions had lower 18F-FDG uptake,26,27 while others found
EGFR mutant tumors had higher 18F-FDG uptake.28 In addi-
tion, the association between the histological subtypes of
adenocarcinoma and EGFR mutations is also controversial. A
number of clinical studies suggested that bronchioloalveolar
carcinomas or tumors with bronchioloalveolar features were
more likely to have EGFR mutations.29–31 Recent genetic
correlation studies; however, found a close correlation be-
tween papillary and micropapillary growth pattern and EGFR
mutations.10
This study has several limitations. First, we only en-
rolled tumors 1 cm in size; therefore, the results may not
apply to tumors less than 1 cm (many bronchioloalveolar
carcinomas are in this category). We excluded these small
tumors because we assessed that the spatial resolution of PET
imaging may underestimate their SUV, resulting in inappro-
priate evaluation of the relationship between the 18F-FDG
uptake and histological growth pattern of tumors. Survival
analysis was not performed due to the limited case number
and follow-up time. Previous studies have shown that a solid
growth pattern and high SUV are both poor prognostic
factors. This study provided a direct link between them, and
the results of survival analysis seem unlikely to influence it.
In addition, we showed a link between TRU-type histology
and low SUV, suggesting that TRU-type lung adenocarcinoma
has better prognosis than the non-TRU type, which needs to be
analyzed in a larger database. Third, we were not able to map the
distribution of SUV and histological growth pattern in the same
tumor. We did observe a correlated distribution of GLUT-1
expression and a specific histological growth pattern. A prospec-
tively designed study using the next generation high-resolution
PET machine may help to elucidate it.
In conclusion, lung adenocarcinoma comprises a heter-
ogeneous group of diseases, and the histological subclassifi-
cation possesses both morphological and biological implica-
tions. In this study, we demonstrated that histological
subtypes of lung adenocarcinomas exhibited differential 18F-
FDG uptake on the PET/CT scan. Our results support the
classification strategy used in the new IASLC/ATS/ERS
classification system, which provides more prognostic infor-
mation than the current WHO classification. This study also
suggests that TRU morphology may also have prognostic
implication, which deserves further confirmation.
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